Creative Planning Seagen Inc. Transaction History

Creative Planning

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	BUY	$191.51 - $216.16 $29,492 - $33,288	154 Added 1.29%	12,090 $2.56 Million
Q2 2023 Jul 21, 2023	BUY	$187.64 - $206.25 $110,144 - $121,068	587 Added 5.17%	11,936 $2.3 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $3,062 - $4,873	-24 Reduced 0.21%	11,349 $2.3 Million
Q4 2022 Feb 10, 2023	BUY	$117.37 - $139.17 $13,380 - $15,865	114 Added 1.01%	11,373 $1.46 Million
Q3 2022 Nov 03, 2022	BUY	$135.27 - $180.11 $13,256 - $17,650	98 Added 0.88%	11,259 $1.54 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $146,567 - $241,557	1,347 Added 13.73%	11,161 $1.98 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $58,728 - $77,504	-491 Reduced 4.76%	9,814 $1.41 Million
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $5,702 - $7,634	-40 Reduced 0.39%	10,305 $1.59 Million
Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $27,777 - $33,114	195 Added 1.92%	10,345 $1.76 Million
Q2 2021 Aug 04, 2021	SELL	$135.08 - $161.1 $517,221 - $616,851	-3,829 Reduced 27.39%	10,150 $1.6 Million
Q1 2021 Apr 30, 2021	BUY	$137.51 - $190.8 $286,020 - $396,864	2,080 Added 17.48%	13,979 $1.94 Million
Q4 2020 Jan 29, 2021	BUY	$164.63 - $211.93 $1.96 Million - $2.52 Million	11,899 New	11,899 $2.08 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.